Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

48.95 1.60 +3.38%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) Operating cash flow

Alert me on Operating cash flow

Septerna, Inc.'s operating cash flow for fiscal 2025 was $110.2M, compared with −$67.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was $106.0M. Septerna, Inc. ranks 28th of 603 Biotechnology companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $110.2M —
FY2024 −$67.5M —
FY2023 −$38.7M —

Quarterly newest first

Period Operating cash flow Change
Jun 2026 −$22.2M —
Mar 2026 −$25.6M —
Dec 2025 −$15.0M —
Sep 2025 $168.8M —
8 more quarters

Operating cash flow against peers

Company Operating cash flow
AUPH Aurinia Pharmaceuticals Inc compare $177.2M
SEPN Septerna, Inc. $106.0M
VCEL Vericel Corporation compare $65.3M
PVLA Palvella Therapeutics, Inc. compare −$36.5M
ZYME Zymeworks Inc. compare −$119.3M
IMNM Immunome, Inc. compare −$208.8M
VERA Vera Therapeutics, Inc. compare −$338.7M
BHVN Biohaven Ltd. compare −$472.5M
LKFT Lakefront Biotherapeutics - Sponsored ADR compare −$508.0M

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on SEPN